A Phase 2, Open Label, Randomized Study of Pexa-Vec (JX-594) Administered by Intratumoral Injection in Patients with Unresectable Primary Hepatocellular Carcinoma.

Breitbach CJ, Moon A, Burke J, Hwang TH, Kirn DH.
Methods Mol Biol. 2015;1317:34357. doi: 10.1007/9781493927272_19.

Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer.

Park SH, Breitbach CJ, Lee J, Park JO, Lim HY, Kang WK, Moon A, Mun JH, Sommermann EM, Maruri Avidal L, Patt R, Pelusio A, Burke J, Hwang TH, Kirn D, Park YS.
Mol Ther. 2015 Sep;23(9):153240. doi: 10.1038/mt.2015.109. Epub 2015 Jun 15.

Pexa-Vec double agent engineered vaccinia: oncolytic and active immunotherapeutic.

Breitbach CJ, Parato K, Burke J, Hwang TH, Bell JC, Kirn DH.
Curr Opin Virol. 2015 Aug;13:4954. doi: 10.1016/j.coviro.2015.03.016. Epub 2015 Apr 17. Review.

Oncolytic viruses: perspectives on clinical development.

Burke J, Nieva J, Borad MJ, Breitbach CJ.
Curr Opin Virol. 2015 Aug;13:5560. doi: 10.1016/j.coviro.2015.03.020. Epub 2015 May 16. Review.

Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaques.

Evgin L, Acuna SA, Tanese de Souza C, Marguerie M, Lemay CG, Ilkow CS, Findlay CS, Falls T, Parato KA, Hanwell D, Goldstein A, Lopez R, Lafrance S, Breitbach CJ, Kirn D, Atkins H, Auer RC, Thurman JM, Stahl GL, Lambris JD, Bell JC, McCart JA.
Mol Ther. 2015 Jun;23(6):106676. doi: 10.1038/mt.2015.49. Epub 2015 Mar 25.

View PDF

Phase 1 study of intratumoral Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus, in Pediatric Cancer Patients.

Cripe TP, Ngo MC, Geller JI, Louis CU, Currier MA, Racadio JM, Towbin AJ, Rooney CM, Pelusio A, Moon A, Hwang TH, Burke JM, Bell JC, Kirn DH, Breitbach CJ.
Mol Ther. 2015 Mar;23(3):6028. doi: 10.1038/mt.2014.243. Epub 2014 Dec 22.

View PDF

First-in-man Study of Western Reserve Strain Oncolytic Vaccinia Virus: Safety, Systemic Spread, and Antitumor Activity.

Zeh HJ, DownsCanner S, McCart JA, Guo ZS, Rao UN, Ramalingam L, Thorne SH, Jones HL, Kalinski P, Wieckowski E, O’Malley ME, Daneshmand M, Hu K, Bell JC, Hwang TH, Moon A, Breitbach CJ, Kirn DH, Bartlett DL.
Mol Ther. 2015 Jan;23(1):20214. doi: 10.1038/mt.2014.194. Epub 2014 Oct 8.

View PDF

Oncolytic and Immunotherapeutic Vaccinia Induces Antibody-Mediated Complement-Dependent Cancer Cell Lysis in Humans.

Kim MK, Breitbach CJ, Moon A, Heo J, Lee YK, Cho M, Lee JW, Kim SG, Kang DH, Bell JC, Park BH, Kirn DH, Hwang TH.
Sci Transl Med. 2013 May 15;5(185):185ra63. doi: 10.1126/scitranslmed.3005361.

Randomized dose finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer.

Heo J, Reid T, Ruo L, Breitbach CJ, Rose S, Bloomston M, Cho M, Lim HY, Chung HC, Kim CW, Burke J, Lencioni R, Hickman T, Moon A, Lee YS, Kim MK, Daneshmand M, Dubois K, Longpre L, Ngo M, Rooney C, Bell JC, Rhee BG, Patt R, Hwang TH, Kirn DH.
Nat Med. 2013 Mar;19(3):32936. doi: 10.1038/nm.3089. Epub 2013 Feb 10.

View PDF

Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans.

Breitbach CJ, Arulanandam R, De Silva N, Thorne SH, Patt R, Daneshmand M, Moon A, Ilkow C, Burke J, Hwang TH, Heo J, Cho M, Chen H, Angarita FA, Addison C, McCart JA, Bell JC, Kirn DH.
Cancer Res. 2013 Feb 15;73(4):126575. doi: 10.1158/00085472. CAN122687. Epub 2013 Feb 7.

View PDF

Targeted and Armed Oncolytic Poxviruses for Cancer: the Lead Example of JX-594.

Breitbach CJ, Thorne SH, Bell JC, Kirn DH.
Curr Pharm Biotechnol. 2012 Jul;13(9):176872. Review.

The Oncolytic Poxvirus JX-594 Selectively Replicates in and Destroys Cancer Cells Driven by Genetic Pathways Commonly Activated in Cancers.

Parato KA, Breitbach CJ, Le Boeuf F, Wang J, Storbeck C, Ilkow C, Diallo JS, Falls T, Burns J, Garcia V, Kanji F, Evgin L, Hu K, Paradis F, Knowles S, Hwang TH, Vanderhyden BC, Auer R, Kirn DH, Bell JC.
Mol Ther. 2012 Apr;20(4):74958. doi: 10.1038/mt.2011.276. Epub 2011 Dec 20.

View PDF

A Mechanistic Proof-of-concept Clinical Trial with JX-594, a Targeted Multi-mechanistic Oncolytic Poxvirus, in Patients With Metastatic Melanoma.

Hwang TH, Moon A, Burke J, Ribas A, Stephenson J, Breitbach CJ, Daneshmand M, De Silva N, Parato K, Diallo JS, Lee YS, Liu TC, Bell JC, Kirn DH.
Mol Ther. 2011 Oct;19(10):191322. doi: 10.1038/mt.2011.132. Epub 2011 Jul 19.

View PDF

Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans.

Breitbach CJ, Burke J, Jonker D, Stephenson J, Haas AR, Chow LQ, Nieva J, Hwang TH, Moon A, Patt R, Pelusio A, Le Boeuf F, Burns J, Evgin L, De Silva N, Cvancic S, Robertson T, Je JE, Lee YS, Parato K, Diallo JS, Fenster A, Daneshmand M, Bell JC, Kirn DH.
Nature. 2011 Aug 31;477(7362):99102. doi: 10.1038/nature10358.

Sequential Therapy with JX-594, a Targeted Oncolytic Poxvirus, Followed by Sorafenib in Hepatocellular Carcinoma: Preclinical and Clinical Demonstration of Combination Efficacy.

Heo J, Breitbach CJ, Moon A, Kim CW, Patt R, Kim MK, Lee YK, Oh SY, Woo HY, Parato K, Rintoul J, Falls T, Hickman T, Rhee BG, Bell JC, Kirn DH, Hwang TH.
Mol Ther. 2011 Jun;19(6):11709. doi: 10.1038/mt.2011.39. Epub 2011 Mar 22.

Redemption for the Field of Oncolytic Virotherapy.

Kirn DH.
Mol Ther. 2011 Apr;19(4):6278. doi: 10.1038/mt.2011.45. No abstract available.

Navigating the clinical development landscape for oncolytic viruses and other cancer therapeutics: No shortcuts on the road to approval.

Breitbach CJ, Reid T, Burke J, Bell JC, Kirn DH.
Cytokine Growth Factor Rev. 2010 AprJun;21(23):859. doi: 10.1016/j.cytogfr.2010.02.001. Epub 2010 May 15. Review.

Double trouble for tumours: Exploiting the tumour microenvironment to enhance anticancer effect of oncolytic viruses.

De Silva N, Atkins H, Kirn DH, Bell JC, Breitbach CJ.
Cytokine Growth Factor Rev. 2010 AprJun;21(23):13541. doi: 10.1016/j.cytogfr.2010.02.007. Epub 2010 Mar 24. Review.

Oncolytic virotherapy for advanced liver tumours.

Chang JF, Chen PJ, Sze DY, Reid T, Bartlett D, Kirn DH, Liu TC.
J Cell Mol Med. 2009 Jul;13(7):123847. doi: 10.1111/j.15824934.2008.00563. x. Epub 2008 Oct 23. Review.

View PDF